iBio (IBIO) director awarded 13,500 stock options at $1.00

Q: How many IBIO shares are covered by the director’s stock option grant?

The stock option grant covers 13,500 shares of iBio, Inc. common stock, as reported in the Form 4.

Q: When do the IBIO director stock options vest?

The options vest pro rata on a monthly basis over twelve months commencing on the grant date of 11/20/2025.

Q: Is the IBIO director’s stock option ownership direct or indirect?

The Form 4 states that the 13,500 stock options are held with direct ownership by the reporting person.

iBio, Inc. reported a stock-based compensation grant to one of its directors.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

iBio, Inc. reported a stock-based compensation grant to one of its directors. On 11/20/2025, the director received a stock option to purchase 13,500 shares of iBio common stock at an exercise price of $1.00 per share. The option becomes exercisable gradually, vesting in equal monthly installments over twelve months starting on the grant date, and expires on 11/19/2035 if not exercised. The filing indicates the director holds these options directly.

Insider Trade Summary

Grant/Award: 13,500 shares

Grant/Award 1 txn

Insider Arkowitz David

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	13,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 13,500 contracts (Direct)

Footnotes (1)

F1. These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IBIO report in this Form 4?

The company reported a grant of stock options to a director, covering 13,500 shares of iBio, Inc. common stock at an exercise price of $1.00 per share.

What is the exercise price of the new IBIO director stock options?

The stock options granted to the director have an exercise price of $1.00 per share of iBio, Inc. common stock.

How many IBIO shares are covered by the director’s stock option grant?

The stock option grant covers 13,500 shares of iBio, Inc. common stock, as reported in the Form 4.

When do the IBIO director stock options vest?

The options vest pro rata on a monthly basis over twelve months commencing on the grant date of 11/20/2025.

When do the IBIO director stock options expire?

The director’s stock options expire on 11/19/2035 if they are not exercised before that date.

Is the IBIO director’s stock option ownership direct or indirect?

The Form 4 states that the 13,500 stock options are held with direct ownership by the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/24/2025 - 04:05 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Arkowitz David

(Last)

(First)

(Middle)

C/O IBIO, INC.

11750 SORRENTO VALLEY, ROAD, SUITE 200

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
iBio, Inc. [ IBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)⁽¹⁾	$1	11/20/2025		A		13,500⁽¹⁾		⁽¹⁾	11/19/2035	Common Stock	13,500	$0	13,500	D

Explanation of Responses:

1. These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

	/s/ Marc Banjak, Attorney-in-fact	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR